Introduction
Paraneoplastic neurological syndromes (PNS) occur with increased frequency in patients with cancer and are not caused by metastasis, direct infiltration of the tumor, or known indirect mechanisms like toxicity, ectopic secretion of hormones, or induced coagulopathies. When originally described, the cause of PNS was unknown. Presently, the accepted hypothesis is that many PNS are caused by immune mechanisms triggered against antigens that are normally present in the nervous system and ectopically expressed by the tumor (onconeural antigens). The basis of this hypothesis is the identification of antibodies against onconeural antigens in serum and CSF of many patients with PNS. 1 The frequency of PNS is low; they occur in less than 1% of patients with solid tumors, particularly small-cell lung carcinoma (SCLC), breast and ovarian cancers. The frequency is probably lower in Hodgkin lymphoma (HL) and other lymphomas. However, the correct diagnosis of PNS is important because an early recognition of a neurological syndrome as paraneoplastic often leads to the discovery and treatment of the underlying tumor which is a crucial step in the management of the PNS. 1 For personal use only. on October 4, 2017. by guest www.bloodjournal.org From
Diagnostic criteria of PNS
The presence of a neurological syndrome of unclear etiology at the time of the diagnosis of a tumor does not necessarily mean that the neurological syndrome is paraneoplastic, as this could represent the coincidental occurrence of two unrelated events. In 2004, two levels of diagnostic certainty were proposed for PNS: definite and possible. The criteria used to define the level are based on the type of neurological syndrome, the detection of well-characterized onconeural antibodies, and the presence of a cancer ( Figure 1 ). 2 Some PNS are termed "classical" because they almost always indicate the presence of an underlying tumor (Table   1 ). These syndromes are considered definite PNS if the tumor is found or the patient has a well-characterized onconeural antibody. "Non-classical" syndromes, such as sensorimotor neuropathy, would qualify as a definite PNS only if the patient has a well-characterized onconeural antibody or the syndrome improves after successful treatment of the underlying tumor ( Figure 1 ). 2 "Well-characterized" onconeural antibodies are those that are demonstrated with validated tests, and for which there are a number of published reports defining the specificity and sensitivity of the antibody for PNS and confirmation of the findings by several investigators. 2 Since the publication of the PNS criteria in 2004, 2 two onconeural antibodies should be added to the list of well-characterized onconeural antibodies:
Sox1 antibodies which are markers of an underlying SCLC in patients with paraneoplastic cerebellar degeneration (PCD) or Lambert-Eaton myasthenic syndrome (LEMS), 3, 4 and Tr antibodies with are markers of HL in patients with PCD. 5 The Tr antigen has been recently identified as delta/notch-like epidermal growth factor-related receptor (DNER). 6 The recently described antibodies against neuronal cell surface or synaptic receptors are not included in the group of well-characterized onconeural antibodies because they are excellent markers (and appear to be pathogenic) of the neurological syndrome, but may occur in patients with or without cancer ( Table 2) . 7 For these cell surface or synaptic antibodies the patients, 16 of them with HL, and demyelinating neuropathies in 11, nine with NHL. 17 PNS that occur in lymphomas have several important differences compared with those in solid tumors. First, lymphomas associate with unique PNS (granulomatous angiitis, hypothermia) whereas classical PNS (sensory neuronopathy, LEMS) rarely occur. Second, onconeural antibodies are absent in most PNS (Table 1) , only Tr and mGluR5 are considered good markers of an underlying HL. This is a limitation to define as definite many PNS that associate with lymphomas. Third, onconeural antigens are not expressed in the tumor cells suggesting the tumor itself may not trigger the PNS. Fourth, unlike solid tumors, lymphomas of patients with PNS do not usually have limited extension at the time of diagnosis. In Table   1 and the text below we summarize the PNS that have been described in HL and NHL. The type and frequency of PNS is different between HL and NHL. The global incidence of PNS is probably higher in HL. Limbic encephalitis and PCD are almost exclusively seen in patients with HL whereas sensorimotor neuropathies and dermatomyositis are more common in NHL.
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Limbic encephalitis
Patients with LE develop short-term memory loss or amnesia, disorientation, confusion, depression, anxiety, or frank psychosis with visual or auditory hallucinations, or paranoid ideation. Generalized or partial complex seizures occur in about 50% of the patients. Hodgkin lymphoma is the third most common cause of LE after SCLC and testicular germ-cell tumors. 18 The cases reported in the English literature are summarized in Table 3 . The association of LE with HL is also known as Ophelia syndrome. 19 The clinical and MRI features ( Figure 2 ) are not different from those reported in LE associated with other tumors.
However, the LE of patients with HL has a better prognosis; frequently, successful treatment of the tumor is sufficient to result in full neurological recovery. This is probably related to the finding that this type of LE occurs in association with an antibody against the metabotropic glutamate receptor 5 (mGluR5) that probably results in reversible neuronal dysfunction rather than neuronal death ( Figure 3 ). 16 The diagnosis of LE requires electroencephalographic, neuroradiological, or pathological evidence of involvement of the medial temporal lobes and amygdala. 18 It is important to apply these criteria to avoid labeling as LE, patients with other disorders that may also associate with HL. 31 The application of these criteria revealed 2 patients, aged 14 and 18 years, reported as LE who in fact probably had other forms of encephalitis. Both cases presented with fever, headache, nausea and vomiting, and CSF pleocytosis followed in a few days by progressive confusion, agitation, hallucinations (one patient) and seizures, requiring intubation. Brain MRI was initially normal and both patients made excellent recovery after treatment of the HL.
32, 33
Unlike HL, LE is extremely rare in patients with NHL, with only a few cases described, mostly in the Japanese literature. 34, 35 As in some HL cases, the criteria for LE were not fulfilled in two patients. 36, 37 In a third patient, the syndrome attributed to LE occurred after an show small vessel " beading" suggestive of vasculitis but in general it has low sensitivity.
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Unlike patients reported in previous decades, recent cases of granulomatous angiitis of the CNS and HL had full recovery after treatment with steroids and chemotherapy for the underlying HL (Table 4) .
Paraneoplastic cerebellar degeneration
PCD is one of the best characterized PNS and occurs preferentially associated with ovarian, breast, SCLC or HL. 47 Only a few cases of PCD associated with NHL have been reported. 17, [48] [49] [50] The pathological hallmark of PCD is a severe loss of Purkinje cells of the PCD antedates the diagnosis of HL in 80% of the patients. 5 The most useful diagnostic test is the detection of onconeural antibodies. Patients with PCD and HL may harbor in their serum and CSF, Tr antibodies (named after the author that first identified them 51 ) ( Figure 4 ). 52 The target antigen of these antibodies is DNER, 6 a transmembrane protein that is preferentially expressed in the dendrites of Purkinje cells and likely plays a regulatory role in dendrite patterning. 53 Unlike other PNS antigens, DNER has not been identified in tissue samples of HL suggesting that the immune response is not triggered by ectopic tumor expression of the antigen. 6 Antibodies against the metabotropic glutamate receptor 1 (mGluR1) were initially described in two patients who developed subacute cerebellar ataxia two and nine years after HL. Subsequent case reports have not confirmed the association of PCD and mGluR1
antibodies with HL.
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Although DNER is a cell surface antigen, PCD related to antibodies against this antigen does not respond as well to treatment as other disorders associated to antibodies against cell surface antigens (Table 2 ). Yet, the prognosis is still better than that of PCD associated with solid tumors. 47 In the two largest series of PCD and HL with a total of 49 patients, 7 (14%) had full recovery or partial neurological improvement. 5, 56 Patients younger than 40 years were more likely to improve and a few had spontaneous improvement. The Tr (or DNER)
antibody titers usually disappear after treatment of the HL.
5
Paraneoplastic chorea
A paraneoplastic etiology is rarely considered in the differential diagnosis of chorea.
However, 56 well documented cases have been reported, 4 of them associated with NHL and one with HL. 57, 58 The chorea was generalized and associated with peripheral neuropathy or encephalopathy in two patients. Brain MRI may demonstrate bilateral hyperintensity of caudate nuclei and putamen, as can be seen in paraneoplastic chorea associated with other tumors, mainly SCLC. 59 The most useful diagnostic test is determination of CV2/CRMP5
antibodies, which are often detected in patients with paraneoplastic chorea regardless of the tumor association. 60 Yet, almost 50% of patients with paraneoplastic chorea with solid tumors or lymphomas do not have onconeural antibodies. Neurological improvement may occur after immunotherapy or treatment of the lymphoma but a complete remission is rarely achieved.
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Opsoclonus-myoclonus syndrome
Opsoclonus is defined by irregular, continuous, large amplitude conjugate saccades in all directions of gaze. In the opsoclonus-myoclonus syndrome, the abnormal eye movements are associated with arrhythmic action myoclonus that involves trunk, limbs, and head, along with truncal ataxia, dysarthria and in some patients' confusion and coma. Opsoclonus may result from a wide variety of causes, the most frequent being post-infectious, idiopathic, and paraneoplastic. 61 In children, paraneoplastic opsoclonus-myoclonus occurs in association with neuroblastoma. In adults, the syndrome is mainly associated with breast cancer and gynecologic tumors (usually accompanied by the presence of Ri antibodies) and SCLC (usually without paraneoplastic antibodies), 62 Only four patients with this syndrome and 
Paraneoplastic myelopathy
Paraneoplastic involvement of the spinal cord presents with subacute myelitis, and rapidly ascending paralysis accompanied by a sensory level. 73 The syndrome has been described in patients with solid tumors and lymphomas. In the latter, the possibility of a toxic or infectious origin was not completely ruled-out. 74 The initial patients reported developed a severe and irreversible paraplegia, and post-mortem studies of two cases revealed widespread spinal cord necrosis without prominent inflammatory infiltrates or vasculitis (necrotizing myelopathy). 74 This type of myelopathy has been described in a few cases with HL and NHL. 75, 76 In the last decade, patients reported with paraneoplastic myelopathies have had better outcomes, and in one study 31% of cases improved with treatment. 73 The MRI usually shows a longitudinally extensive (>3 vertebral segments) T2 increased signal abnormality that may enhance with gadolinium. Onconeural antibodies (mainly amphiphysin and CV2/CRMP5 antibodies) may be present in serum or CSF, supporting the paraneoplastic origin of the myelitis. However, patients with HL or NHL can be seronegative, and some cases were not tested for onconeural antibodies.
73,77

Paraneoplastic neuronopathies
The term neuronopathy indicates that the primary damage occurs in the cell body of neurons that form the peripheral nerves. There are PNS that target a specific neuronal type and cause pure motor, sensory, or autonomic neuronopathies and others that damage more than cell type leading to a mixed neuronopathy. The latter situation is more frequent in the setting of SCLC and Hu antibodies. 78 Paraneoplastic motor neuronopathies have been described in a few patients who almost always had HL. The syndrome defined as subacute motor neuropathy, has only rarely been reported since the initial description in 1979. 79 Patients develop motor weakness that tends to be greater in the legs and proximal muscles. Muscle weakness is rarely severe and sometimes stabilizes or improves without any specific treatment. The symptoms appear when the HL is already diagnosed or in remission. Some patients developed the disorder after treatment with mantle and para-aortic radiotherapy and radiation toxicity could not be completely ruled-out. 79 In other cases the patients had more severe and diffuse weakness antedating the diagnosis of HL. Although some pathological reports show loss of motor neurons in the anterior horn of the spinal cord, the clinical improvement in some Deep tendon reflexes are abolished or diminished. Electromyography and nerve conduction velocities are helpful in confirming that the involvement is restricted to the sensory nerves.
The prognosis is poor and patients rarely improve.
Paraneoplastic sensory neuronopathy has only been reported in a few patients mainly with HL; onconeuronal antibodies are negative. [81] [82] [83] [84] However, we evaluated a patient with this neuropathy and NHL who had Ma2 antibodies (unpublished). There are also a few case reports of patients with a subacute sensory neuropathy that had complete recovery after treatment of the HL. These cases probably represent sensory variants of inflammatory demyelinating neuropathies rather than true neuronopathies. 85 When the neuronal bodies of autonomic ganglia are affected, patients develop subacute pandysautonomia with impairment of sympathetic (orthostatic hypotension, anhydrosis) and parasympathetic function (impaired pupillary responses, dry mouth, gastrointestinal dysmotility, erectile dysfunction, and fixed heart rate). 86 The syndrome rarely has a paraneoplastic origin and is frequently associated with nicotinic acetylcholine receptor antibodies. The presence of these antibodies helps to confirm the neurological diagnosis but does not establish a paraneoplastic etiology. 86 The association of autoimmune autonomic ganglionopathy with lymphomas is exceptional. 87, 88 One of the reported cases improved after
For personal use only. on October 4, 2017. by guest www.bloodjournal.org From treatment with rituximab. 88 A limited form of autonomic ganglionopathy is the occurrence of an isolated tonic (Adie) pupil that has been described in patients with cancer, including one with HL and Tr (DNER) atibodies. 89 An intriguing symptom identified in a few patients with HL is hypothermia. Severe episodes of hypothermia were reported in 17 patients with advanced stage HL usually during chemotherapy. The cause of these episodes is unknown.
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Paraneoplastic sensorimotor neuropathies
Paraneoplastic sensorimotor neuropathies that precede the diagnosis of lymphomas are mainly demyelinating neuropathies that may fulfill diagnostic criteria of Guillain-Barré syndrome (GBS) or chronic inflammatory demyelinating polyneuropathy (CIDP). 91 The clinical course is usually subacute, and onconeural antibodies are negative. Paraneoplastic neuropathies are more common in HL and NHL with monoclonal bands. Although the frequency of cancer in patients with GBS is not increased, the association between this neuropathy and HL is well established. 92 Patients with NHL and monoclonal gammopathy can develop typical CIDP or predominantly sensory neuropathies that are likely mediated by antibody activity of the monoclonal IgM against myelin-associated glycoprotein or gangliosides. 93, 94 On the other hand, neuropathies associated with large B-cell lymphomas may be caused by direct infiltration of the peripheral nerves (neurolymphomatosis). 95 In a recent study of 32 patients with neuropathy and NHL, 15 were considered to have neurolymphomatosis whereas only 5 were paraneoplastic. In the other 12 patients the etiology was uncertain and all but two developed a syndrome of multifocal mononeuropathy suggestive of neurolymphomatosis. 94 Although infiltrative neuropathies usually are asymmetric or show a pattern of multifocal mononeuropathy, they can be indistinguishable from CIDP and even respond to steroids. 94 The diagnosis is usually confirmed by the demonstration of malignant cells in the nerve biopsy or more rarely in the CSF ( Figure 5 ). 
Vasculitic neuropathy
Isolated vasculitis of peripheral nerves has been reported in a few patients with solid tumors and lymphomas. 96 The clinical course is characterized by a progressive, initially asymmetric, painful sensorimotor neuropathy. Electromyography and nerve conduction studies demonstrate findings compatible with multifocal neuropathy or diffuse axonal polyneuropathy with asymmetric involvement. 97 Combined biopsy of nerve and muscle is indicated because this increases the chance of identifying the vasculitis. Nerve biopsy shows intramural and perivascular inflammatory infiltrates, usually without necrotizing vasculitis.
98
Paraneoplastic syndromes of the neuromuscular junction and muscle
The most frequent PNS of the muscle in patients with lymphoma is dermatomyositis. 99 Some patients with lymphoma develop polymyositis, but the frequency of this association is much lower than that with dermatomyositis. Cancer-associated myositis (dermato-and polymyositis) occurs in patients older than 50 years and is more predominant in NHL. 99 In approximately 50% of patients the myositis is diagnosed before the discovery of the lymphoma. Thus, a search for an underlying cancer is indicated in these patients and whole body PET/CT is the preferred test. 100 Immunological studies may also help in identifying patients at risk of developing cancer. The presence of anti-synthetase antibodies is a negative predictor for the presence of cancer. In contrast, detection of the antibody p155, against human transcriptional intermediary factor 1-gamma, shows a sensitivity of 70% and a specificity of 89% for predicting an occult malignancy. The data is more robust for patients with dermatomyositis with only 5% of p155 antibody negative patient's subsequently developing cancer.
101
For personal use only. on October 4, 2017. by guest www.bloodjournal.org From Lymphomas are a rare cause of PNS of the neuromuscular junction. Only a few patients, usually with NHL and LEMS 102 or neuromyotonia have been reported. 103, 104 A few cases of myasthenia gravis have been described in association with HL, and T-cell NHL with involvement of the mediastinum. 105 In 50% of the cases with lymphoma and LEMS or myasthenia the neurological disorder develops around the time of the diagnosis of lymphoma.
For the rest of patients, the lymphoma and neurological disorder are separated by many years suggesting the presence of an underlying immunological disturbance, caused by the tumor or immunosuppression that predisposes to the paraneoplastic immune mediated syndrome.
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